NCT04555837View on ClinicalTrials.gov

Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 15, 2020

Primary Completion Date

April 8, 2025

Study Completion Date

April 8, 2025

Conditions

Head and Neck Squamous Cell CarcinomaMalignant Solid Neoplasm

Interventions

DRUG

Alisertib

Given PO

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT04555837 - Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer | Biotech Hunter | Biotech Hunter